Sarcopenia is a syndrome closely associated with decreased muscle mass and strength as well as decreased physical strength. As gynecologic malignancy surgery often requires extensive multi-organ surgical treatment which may also be accompanied by long-term radiotherapy and immunotherapy leading to a higher incidence of sarcopenia in gynecologic malignancy patients which seriously affects patients' somatic function treatment outcome and quality of life. At the same time there is increasing evidence that sarcopenia shortens progression - free survival increases toxic side effects of chemotherapy and the incidence of postoperative complications in patients with gynecologic malignancies. This article reviews sarcopenia in patients with gynecologic malignancies summarizing screening and assessment methods influencing factors and nonpharmacological interventions respectively with the aim of helping clinical staff to better understand sarcopenia in patients with gynecologic malignancies and providing a reference for the development of targeted sarcopenia management strategies.